Market News AIOpen the app

BBOT stock news · BridgeBio Oncology Therapeutics, Inc.

Stories about BridgeBio Oncology Therapeutics, Inc. (BBOT) from the last 90 days, each explained in plain English with whether the news reads good or bad for the company.

Get alerts for BBOT

Follow BridgeBio Oncology Therapeutics, Inc. (BBOT) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for BBOT
Free on the App Store and Google Play, or on the web.
  1. Nov 10, 2026, 4:23 PM ET · Market

    BridgeBio Oncology says how it’s doing financially and its recent results.

    Neutral

    BBOT filed an SEC report and listed a press release dated November 10, 2026. The supplied text gives no results, so it does not change the company's outlook.

  2. Oct 20, 2026, 7:20 PM ET · Market

    Oppenheimer has lowered its price goal for BridgeBio Oncology Therapeutics to $16.

    Neutral

    Oppenheimer lowered BBOT's price target to $16 per share from $22, but kept its Outperform rating. The mixed call does not show a clear change in BBOT's business prospects.